15th July 2019
Telomium, one of the winners of the French Innovation Journey from Education to Business
After applying the vaccine to three monkeys without secondary reactions, Telomium continues to develop their immunotherapy product against cancer.
Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Their first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase.
After defining the best use of their product, Telomium plans to raise founds in order so start their regular preclinical development then performing clinical trials in humans and setting a deal with a big pharma group
EHDS report connects innovators and European Commission
Report supports Euopean Commission's EHDS creation
EIT HEI Initiative launches new call for proposals
Improving HEI innovation capacity
24 start-ups selected for Bridgehead programme
Support to expand presence to new markets